The NeoChord Artificial Chordae Delivery System is a beating heart procedure, echo-guided treatment option for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. LEARN MORE ABOUT THE PROCEDURE BY THE NUMBERS | NeoChord in the World 0 Countries 0+ Study Patients 0+ Publications
Show more
See More
Aug 14, 2018 . The NeoChord device, in illustration, is inserted in the beating heart through a small incision, guided by echocardiography “While the heart is beating, you make a small incision under the patient’s left nipple, insert the device, and implant the artificial chords to the mitral valve,” says Dr. El-Eshmawi, the site Principal Investigator for the study.
Show more
See More
Jan 08, 2013 . Tech Update: NeoChord Mitral Valve Repair Device Gets CE Mark. By Adam Pick on January 8, 2013. As we continue to monitor the newest technologies enhancing valvular therapy, I though you might like to know that the NeoChord mitral valve repair system recently received a CE mark for use in Europe. This unique device, which is not FDA approved in ...
Show more
See More
NeoChord ConsultConnect and ConnectCARD is a medical consultation and service related to delivery of artificial chordae tendineae for treatment of mitral insufficiency.The NeoChord Artificial Chordae Delivery System, Model DS1000, meets the essential requirements referred to in Article 3 of the MDD 93/42/EEC and is labeled with the CE marking of conformity.
Show more
See More
Oct 16, 2009 . Digital animation of beating-heart, sternal-sparing implantation of artificial chordae tendineae enabled by NeoChord's surgical device -- a minimally-invasiv...
Show more
See More
NeoChord, Inc., a Minneapolis-based medical technology start-up, obtained an exclusive license for D. Speziali’s technology and partnered with Worrell to develop the device. Worrell’s researchers began by conducting an operative immersion, documenting preliminary feedback from surgeons performing similar procedures on animal specimens.
Show more
See More
Jun 17, 2016 . Randomized Trial of the NeoChord DS1000 System Versus Open Surgical Repair (ReChord) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by …
Show more
See More
Apr 30, 2018 . NeoChord DS1000 System Successfully Treats 20th Patient in Combination with Other Beating Heart Procedures. April 30, 2018 09:00 ET | Source: NeoChord, Inc. NeoChord, Inc. St. Louis Park ...
Show more
See More
NeoChord is a medical device company that has developed a proprietary device that allows mitral valve repair to be performed on a beating heart through a 2 to 3-inch incision between the ribs in patients with severe, degenerative mitral valve regurgitation. In contrast, most mitral valve repair procedures are performed through a 3 to 10-inch chest
Show more
See More
cal outcomes of the NeoChord procedure after failed conventional mitral valve repair. A total of 312 patients were treated with the NeoChord repair procedure between January 2014 and December 2018 at 5 European cen-ters. Clinical and echocardiographic data were reviewed to identify patients who had a prior surgical mitral valve repair procedure.
Show more
See More
Jan 29, 2013 . The placement of at least one NeoChord using the DS1000 System AND a reduction in mitral regurgitation <= 2+ at the time of the procedure AND maintained MR reduction of <= 2+ at 30 days. Secondary Outcome Measures : Procedural Safety [ Time Frame: 30 days ] the rate of Major Adverse Events (MAE) defined as a combined endpoint of: death, MI ...
Show more
See More
Feb 11, 2016 . InEK, the German Institute for the Hospital Renumeration System, has granted the NeoChord DS1000 mitral valve repair system NUB (Neue Untersuchungs- und Behandlungsmethoden) status 1.The NUB process enables the introduction of new medical products prior to formal reimbursement eligibility and introduces the cost of a new procedure, …
Show more
See More
Oct 28, 2016 . NeoChord Again Awarded NUB Status 1 In Germany. 2/10/2016. NeoChord Appoints Lori Adels, Ph.D. As Vice President Of Clinical Affairs, Regulatory And Quality. 10/20/2015. NeoChord Bags $12.6 Million for Mitral Valve Repair Tool That Works Without Stopping the Heart. 5/26/2015. NeoChord Appoints David Chung As President And CEO. …
Show more
See More
NeoChord, Inc. is a privately held medical technology company leading the advancement of minimally invasive repair for degenerative mitral regurgitation (DMR).
Show more
See More
Feb 26, 2017 . NeoChord-papillary muscle security is obligatory and must mirror native chord anatomy and function. The two “base” sutures should be passed in an anterior to posterior direction through the papillary muscle in parallel and toward the respective prolapsed segment (Fig. 17.5a).The knotted end of the loop should be tied opposite the prolapsing leaflet surface …
Show more
See More
NeoChord is a medical device company that has developed a proprietary device that allows mitral valve repair to be performed on a beating heart through a 2 to 3 inch incision between the ribs in patients with severe, degenerative mitral valve regurgitation.
Show more
See More
The NeoChord Artificial Chordae Delivery System is a beating heart procedure, echo-guided treatment option for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. This opens in a new window.
Tech Update: NeoChord Mitral Valve Repair Device Gets CE Mark. This unique device, which is not FDA approved in America, enables minimally invasive implantation of artificial chordae using a catheter-based approach. If you did not know, the chordae support the mitral valve leaflets as they open-and-close to move the blood through your heart.
In November 2016, David H. Adams, MD, performed the first NeoChord procedure in the United States, in a trial exploring the efficacy of beating-heart mitral valve repair, without the use of cardiopulmonary bypass, through a minithoracotomy. A clinical study is ongoing within the United States to evaluate the use of the NeoChord DS1000.
The first 50 patients of the TACT study are scheduled to undergo the NeoChord procedure during the first three months of this year. Dr. Giovanni Speziali, one of the proctors of the study from the University of Pittsburgh Medical Center, stated: